PCWG4 updates prostate cancer trial guidelines with patient-centered and biomarker-driven approaches.
Prostate Cancer Working Group 4 Recap.
Aravind S Ravi Kumar, Aaron R Hansen
European urology focus · Jun 2026 · Q1 in Urology
Background
The Prostate Cancer Clinical Trials Working Group (PCWG) recommendations have guided the design and interpretation of prostate cancer trials for more than two decades.
Methods
PCWG4 introduces a shift towards patient-centred terminology and end points, incorporating molecular and imaging biomarkers for trial eligibility and response assessment.
More results
PCWG4 emphasises the use of patient-reported outcome measures and introduces the concept of "no longer clinically benefitting" to guide treatment continuation beyond conventional progression end points.
“
Conclusion
This recap summarises key updates in PCWG4 and highlights their implications for contemporary prostate cancer clinical trial design and interpretation.